E. Joosens

1.2k total citations
26 papers, 587 citations indexed

About

E. Joosens is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, E. Joosens has authored 26 papers receiving a total of 587 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 9 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in E. Joosens's work include Glioma Diagnosis and Treatment (11 papers), Brain Metastases and Treatment (5 papers) and Colorectal Cancer Treatments and Studies (3 papers). E. Joosens is often cited by papers focused on Glioma Diagnosis and Treatment (11 papers), Brain Metastases and Treatment (5 papers) and Colorectal Cancer Treatments and Studies (3 papers). E. Joosens collaborates with scholars based in Belgium, United States and Netherlands. E. Joosens's co-authors include Jacques De Grève, Bart Neyns, Lionel D’Hondt, C. Chaskis, Alex Michotte, Jan Sadones, Pieter In 'T Veld, Jean‐François Baurain, Frank Bouttens and Luc Verbeke and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

E. Joosens

25 papers receiving 574 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Joosens Belgium 11 258 225 173 133 102 26 587
Emel Yaman Türkiye 11 160 0.6× 88 0.4× 131 0.8× 112 0.8× 47 0.5× 41 419
Chang-Hsien Lu Taiwan 11 174 0.7× 98 0.4× 79 0.5× 159 1.2× 87 0.9× 15 566
L. Pronk Netherlands 10 314 1.2× 178 0.8× 187 1.1× 83 0.6× 41 0.4× 20 557
Antonio Santo Italy 16 357 1.4× 107 0.5× 402 2.3× 121 0.9× 83 0.8× 55 786
M. Synodinou Greece 10 179 0.7× 220 1.0× 519 3.0× 82 0.6× 131 1.3× 24 844
P. Karageorgis Greece 7 305 1.2× 370 1.6× 572 3.3× 84 0.6× 85 0.8× 18 789
Kazushige Tsutsui Japan 14 186 0.7× 207 0.9× 260 1.5× 118 0.9× 214 2.1× 31 858
K. Park South Korea 13 664 2.6× 62 0.3× 482 2.8× 196 1.5× 201 2.0× 43 994
Don W. Shaffer United States 8 407 1.6× 151 0.7× 151 0.9× 138 1.0× 117 1.1× 11 678
D. Antonadou Greece 12 383 1.5× 380 1.7× 784 4.5× 113 0.8× 144 1.4× 32 1.2k

Countries citing papers authored by E. Joosens

Since Specialization
Citations

This map shows the geographic impact of E. Joosens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Joosens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Joosens more than expected).

Fields of papers citing papers by E. Joosens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Joosens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Joosens. The network helps show where E. Joosens may publish in the future.

Co-authorship network of co-authors of E. Joosens

This figure shows the co-authorship network connecting the top 25 collaborators of E. Joosens. A scholar is included among the top collaborators of E. Joosens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Joosens. E. Joosens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vulsteke, Christof, Setsuko K. Chambers, M.J. Rubio Pérez, et al.. (2024). Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy. European Journal of Cancer. 208. 114157–114157. 3 indexed citations
2.
Robijns, Jolien, et al.. (2023). Evaluation of a novel skin care product for the management of chemotherapy–related dermatologic toxicities: A quasi-experimental study. European Journal of Oncology Nursing. 63. 102278–102278. 1 indexed citations
3.
Duerinck, Johnny, Paul M. Clément, Frank Bouttens, et al.. (2015). Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma. Journal of Neurology. 262(3). 742–751. 11 indexed citations
4.
Cox, Tony, Ruth Achten, E. Joosens, et al.. (2013). Non-Hodgkin Lymphoma after Treatment with Extended Dosing Temozolomide and Radiotherapy for a Glioblastoma: A Case Report. Case Reports in Oncology. 6(1). 45–49. 1 indexed citations
5.
Neyns, Bart, Jan Sadones, E. Joosens, et al.. (2009). Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Annals of Oncology. 20(9). 1596–1603. 182 indexed citations
6.
Neyns, Bart, Jan Sadones, E. Joosens, et al.. (2008). A Multicenter Stratified Phase Ii Study of Cetuximab for the Treatment of Patients With Recurrent High-grade Glioma. Neuro-Oncology. 10(6). 1067. 8 indexed citations
7.
Neyns, Bart, C. Chaskis, E. Joosens, et al.. (2008). A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma. Cancer Investigation. 26(3). 269–277. 35 indexed citations
8.
Neyns, Bart, Jan Sadones, E. Joosens, et al.. (2008). A multicenter stratified phase II study of cetuximab for the treatment of patients with recurrent high-grade glioma. Journal of Clinical Oncology. 26(15_suppl). 2017–2017. 7 indexed citations
9.
10.
Aelst, F. Van, E. Joosens, Denis Schallier, et al.. (2007). A BELGIAN REGISTRY OF INTERLEUKIN-2 ADMINISTRATION FOR TREATMENT OF METASTATIC RENAL CELL CANCER AND CONFRONTATION WITH LITERATURE DATA. Acta Clinica Belgica. 62(4). 223–229. 2 indexed citations
11.
Sadones, Jan, C. Chaskis, E. Joosens, et al.. (2006). A stratified phase II study of cetuximab for the treatment of recurrent glioblastoma multiforme: Preliminary results. Journal of Clinical Oncology. 24(18_suppl). 1558–1558. 12 indexed citations
12.
Cutsem, Eric Van, Luc Dirix, J-L. van Laethem, et al.. (2005). Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. British Journal of Cancer. 92(6). 1055–1062. 35 indexed citations
13.
Neyns, Bart, Joris Menten, Lionel D’Hondt, et al.. (2005). A phase II study of temozolomide administered 21 out of 28 days for the treatment of patients with recurrent anaplastic (oligo) astrocytoma: An interim analysis of toxicity. Journal of Clinical Oncology. 23(16_suppl). 1560–1560. 3 indexed citations
14.
Schrijvers, D., C. van Herpen, Joseph Kerger, et al.. (2004). Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I–II feasibility study. Annals of Oncology. 15(4). 638–645. 60 indexed citations
15.
Everaert, Els, et al.. (2004). Temozolomide for the Treatment of Recurrent Supratentorial Glioma: Results of a Compassionate use Program in Belgium. Journal of Neuro-Oncology. 70(1). 37–48. 12 indexed citations
16.
Neyns, Bart, et al.. (2004). Temozolomide for the treatment of recurrent glioma: Results of a compassionate use program in Belgium. Journal of Clinical Oncology. 22(14_suppl). 1541–1541. 3 indexed citations
17.
18.
Berwaerts, Joris, et al.. (1997). Role of Hepatic Arterial Embolisation in the Treatment for Metastatic Insulinoma. Acta Clinica Belgica. 52(5). 263–274. 10 indexed citations
19.
Verbeke, Kristin, et al.. (1997). Comparison of modified technetium-99m albumin and technetium-99m red blood cells for equilibrium ventriculography.. PubMed. 38(10). 1521–8. 11 indexed citations
20.
Verhelst, J., et al.. (1995). Pituitary Metastasis Mimicking A Pituitary Adenoma. Acta Clinica Belgica. 50(1). 31–35. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emel Yaman Breakdown of academic impact, for papers by Chang-Hsien Lu Breakdown of academic impact, for papers by L. Pronk Breakdown of academic impact, for papers by Antonio Santo Breakdown of academic impact, for papers by M. Synodinou Breakdown of academic impact, for papers by P. Karageorgis Breakdown of academic impact, for papers by Kazushige Tsutsui Breakdown of academic impact, for papers by K. Park Breakdown of academic impact, for papers by Don W. Shaffer Breakdown of academic impact, for papers by D. Antonadou
Rankless by CCL
2026